Provided By GlobeNewswire
Last update: Aug 26, 2024
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following upcoming investor conferences:
NASDAQ:IOBT (6/12/2025, 6:32:32 PM)
1.5
0 (0%)
Find more stocks in the Stock Screener